

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **(1) RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR**

### **RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) hereby announces that Mr. Li Kin Wai (“**Mr. Li**”) has resigned as the joint company secretaries of the Company (“**Joint Company Secretary**”) and an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) with effect from 26 March 2024.

Mr. Li has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Li for his support to the Company during his term of office.

Following Mr. Li’s resignation, Ms. Peng Yunlu (“**Ms. Peng**”), the other Joint Company Secretary will remain in office as the sole company secretary of the Company. Ms. Peng has been admitted as a member of The Hong Kong Chartered Governance Institute and therefore satisfies the qualification of a company secretary as required under Rule 3.28 and 8.17 of the Listing Rules. Ms. Peng has also been appointed as the Authorised Representative with effect from 26 March 2024 in replacement of Mr. Li.

## **Biographical details of Ms. Peng**

Ms. Peng is primarily responsible for coordinating the meetings of the Board and the shareholders, handling corporate disclosure pursuant to the Listing Rules as well as attending to corporate governance affairs. Ms. Peng joined the Group and has been working for Sichuan Sinco Pharmaceuticals Co., Ltd (“**Sichuan Sinco**”) since 2013. She has held important positions in Quality Management Department, Purchasing Department, Capital Department and Accounting Department in Sichuan Sinco during the period. Ms. Peng is a Chartered Secretary and a Chartered Governance Professional as well as an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Peng holds a master’s degree in international business from University of Birmingham and a master of Corporate Governance degree from the Hong Kong Metropolitan University.

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board of directors is pleased to announce that Mr. Huang Zhijian (“**Mr. Huang**”) has been appointed as an executive director of the Company (“**Executive Director**”), with effect from 26 March 2024, in accordance of article 16.2 as set out in Memorandum and Articles of Association of the Company, until the next annual general meeting of the Company after his appointment and shall then be eligible for re-election at that meeting.

The biographical details of Mr. Huang are set out as follows:

Mr. Huang, aged 31, joined our Group in January 2018 as the assistant product manager of Sichuan Sinco. Mr. Huang was appointed as the general manager of Sichuan Sinco and Qingdao Yusheng Hengying Trading Co., Ltd. (“**Qingdao Yusheng**”) in November 2022 and December 2022, respectively, mainly responsible for overall business operation and management. Mr. Huang is also the director of Sichuan Sinco, Qingdao Yusheng, Sinco Shanghai Trading Co., Ltd., Haikou Sinco Biological Medical Technology Co., Ltd., and Sinco (Hainan) Investment Development Co., Ltd.. From June 2018 to November 2022, he was the sales manager of Sichuan Sinco. Mr. Huang obtained a master’s degree in Business Administration from ESC PAU Business School in 2021 and graduated from Haikou University of Economics in 2020 with a bachelor’s degree in financial management.

Mr. Huang has entered into a service agreement with the Company for an initial term of 3 years commencing from 26 March 2024. Pursuant to the service agreement, either the Company or Mr. Huang may give at least one month’s written notice to the other party for early termination of the service agreement. Mr. Huang is entitled to receive a remuneration of RMB960,000 per annum. The remuneration of Mr. Huang has been determined by the Remuneration Committee with reference to his duties and responsibilities, experience, qualifications and prevailing market conditions and will be subject to annual review. In addition, he is entitled to a discretionary year-end bonus, benefits in kind and pension rights from the Group subject to recommendation and approval by the Remuneration Committee.

As at the date of this announcement, Mr. Huang was deemed to be interested in 1,050,000,000 shares, representing approximately 51.65% of the total number of issued shares, within the meaning of Part XV of the SFO. Mr. Huang is one of the beneficiaries of Fullwealth Holdings Limited, which is a trust and holds the entire beneficial interest in Risun Investments Limited (“**Risun**”). Risun directly holds 1,050,000,000 shares of the Company, representing approximately 51.65% of the total number of issued shares. Save as disclosed, as of the date of this announcement, Mr. Huang does not have any interests or short positions in any shares, underlying shares or debentures of the Company and its associated corporations within the meaning of Part XV of the SFO.

Mr. Huang is the son of Mr. Huang Xiangbin, the Executive Director, chairman of the Board and the substantial shareholder of the Company. Save as disclosed above, as at the date of this announcement, Mr. Huang (i) does not have any relationship with any other directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company; (ii) has not held any directorship in public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; and (iii) does not have any other interests or short positions in the shares, underlying shares or debentures of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed above, there is no other information related to the appointment of Mr. Huang that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Mr. Huang for joining the Board.

By Order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 26 March 2024

*As at the date of this announcement, the executive directors are Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; and the independent non-executive directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*